3-[4-(3-chlorophenyl)-1-ethyl-7-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl]propanoic acid | 337357-62-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-[4-(3-chlorophenyl)-1-ethyl-7-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl]propanoic acid
• 英文别名: 3-[4-(3-chlorophenyl)-1-ethyl-7-methyl-2-oxo-1,8-naphthyridin-3-yl]propanoic acid
• CAS: 337357-62-7
• 化学式: C₂₀H₁₉ClN₂O₃
• 分子量: 370.835
• InChiKey: XYFVLSWIYKWKTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  70.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[4-(3-chlorophenyl)-1-ethyl-7-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl]propanoic acid 在 盐酸 、 sodium borohydrid 、 硫酸 、 碳酸氢钠 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 4-(3-chlorophenyl)-1-ethyl-3-(3-hydroxypropyl)-7-methyl-1,8-naphthyridin-2(1H)-one
  参考文献：
  名称：

  NAPHTHYRIDINE DERIVATIVES

  摘要：

  公开号：

  EP1225173B1
• 作为产物：
  描述：

  sodium hydroxide 、 ethyl 3-[4-(3-chlorophenyl)-1-ethyl-7-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl]propanoate 、 盐酸 在 乙酸乙酯 、 Brine 、 silica gel 、 chloroform methanol 、 ethyl acetate diisopropyl ether 作用下， 以 tetrahydrofuran methanol 为溶剂， 反应 2.0h， 以to obtain 1.27 g of 3-[4-(3-chlorophenyl)-1-ethyl-7-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl]propanoic acid as colorless crystals的产率得到3-[4-(3-chlorophenyl)-1-ethyl-7-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl]propanoic acid
  参考文献：
  名称：

  Naphthyridine derivatives

  摘要：

  2-氧代-1,2-二氢-1,8-萘啶衍生物，其在3位上带有特定取代基——X—R6，在4位上带有环状取代基R5；或其盐。这些衍生物和盐可用作药物，特别是用于与PDE IV有关的呼吸系统疾病的预防或治疗剂。

  公开号：

  US06740662B1

文献信息

• POWDERY MEDICINAL COMPOSITIONS FOR INHALATION AND PROCESS FOR PRODUCING THE SAME
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP1486204A1

  公开（公告）日：2004-12-15

  The present invention provides marked results in that it is possible to present by a simple method a dry powder inhalation for pulmonary delivery that is made from a biologically active substance in crystal form and a biocompatible, electrostatic aggregation-inhibiting substance and that has excellent safety, stability, and pulmonary delivery performance. Moreover, it is also possible to provide sustained release performance that is appropriate for the properties of the biologically active substance by selecting [the appropriate] hydrophobic substance.

  本发明的显著成果是，可以通过简单的方法提供一种用于肺部给药的干粉吸入剂，该干粉吸入剂由晶体状生物活性物质和生物相容性静电聚集抑制物质制成，具有极佳的安全性、稳定性和肺部给药性能。 此外，还可以通过选择[适当的]疏水性物质，提供适合生物活性物质特性的持续释放性能。
• REMEDY FOR CHRONIC PELVIC PAIN SYNDROME
  申请人：Astellas Pharma Inc.

  公开号：EP1685849A1

  公开（公告）日：2006-08-02

  This invention relates to an agent for preventing or treating chronic pelvic pain syndromes (chronic abacterial prostatitis, chronic pelvic pain syndrome in a narrow sense and interstitial cystitis), which comprises various phosphodiesterase 4 (PDE 4) inhibitors such as cilomilast and roflumilast as an active ingredient.

  本发明涉及一种用于预防或治疗慢性盆腔疼痛综合征（慢性细菌性前列腺炎、狭义慢性盆腔疼痛综合征和间质性膀胱炎）的制剂，其活性成分包括各种磷酸二酯酶 4（PDE 4）抑制剂，如西洛米司特和罗氟司特。
• Novel dry powder inhalation for lung-delivery and manufacturing method thereof
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US20040184995A1

  公开（公告）日：2004-09-23

  The present invention provides marked results in that it is possible to present by a simple method a dry powder inhalation for pulmonary delivery that is made from a biologically active substance in crystal form and a biocompatible, electrostatic aggregation-inhibiting substance and that has excellent safety, stability, and pulmonary delivery performance. Moreover, it is also possible to provide sustained release performance that is appropriate for the properties of the biologically active substance by selecting [the appropriate] hydrophobic substance.

  本发明的显著成果是，可以通过简单的方法提供一种用于肺部给药的干粉吸入剂，该干粉吸入剂由晶体状生物活性物质和生物相容性静电聚集抑制物质制成，具有优异的安全性、稳定性和肺部给药性能。 此外，还可以通过选择适当的疏水性物质，提供适合生物活性物质特性的持续释放性能。
• PDE 4 INHIBITORS FOR THE TREATMENT OF INTERSTITIAL CYSTITIS
  申请人：Astellas Pharma Inc.

  公开号：EP1685849B1

  公开（公告）日：2012-01-25
• Agent for treating chronic pelvic pain syndrome
  申请人：Kobayashi Miki

  公开号：US20070167450A1

  公开（公告）日：2007-07-19

  This invention relates to an agent for preventing or treating chronic pelvic pain syndromes (chronic abacterial prostatitis, chronic pelvic pain syndrome in a narrow sense and interstitial cystitis), which comprises various phosphodiesterase 4 (PDE 4) inhibitors such as cilomilast and roflumilast as an active ingredient.